2017•Therapeutics and Clinical Risk ManagementOpen access

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients

Salma Al Dallal

Abstract

Abstract: Ofatumumab Arzerra ® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody’s therapeutic effect on chronic lymphocytic leukemia. Keywords: ofatumumab, cell-mediated cytotoxicity, chronic lymphocytic leukemia

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Ofatumumab, Chronic lymphocytic leukemia, Medicine, CD20, Monoclonal antibody, Cytotoxicity, Antibody, Cancer research